<DOC>
	<DOCNO>NCT02532985</DOCNO>
	<brief_summary>The study assess gastrointestinal tolerability multiple serving novel dietary fiber three different dose level generally healthy men woman . Double-blind control , cross-over clinical trial negative ( added fiber ) positive control . Multiple serve 24h , data collection 24 48h 1 week wash-out cross-overs . 45 randomized , generally healthy men woman , 18-54 , BMI high equal 18.5 small equal 39.99 kg/m2 . Novel dietary fiber ingredient positive control deliver 240 ml beverage .</brief_summary>
	<brief_title>Gastrointestinal Tolerability Following Multiple Servings Novel Dietary Fiber</brief_title>
	<detailed_description>This randomize , double-blind , five test period crossover study consist screen visit ( visit 1 , day -7 ) 10 test visit ( day 0 , 2 , 7 , 9 , 14 , 16 , 21 , 23 , 28 , 30 ) . At screen visit , subject provide informed consent , medical history clinic visit procedure perform . Subjects meet study criterion instruct maintain habitual diet physical activity pattern throughout study period . Subjects also instruct avoid foods/ beverage cause Gastrointestinal ( GI ) -distress , well high-fiber food 24 h prior throughout 48 h test period . Additional instruction include avoid use non-steroidal anti-inflammatory drug ( NSAIDS ) , antacid , proton pump inhibitor ( PPIs ) , H2 receptor antagonists 48 h prior next clinic visit ( visit 2 , day 0 ) . At test visit , eligible subject undergo clinic visit procedure , include assessment adverse event ( AEs ) . At begin test period ( Visits 2 , 4 , 6 , 8 , 10 ) , subject arrive clinic 9-14 h fast administer one serving assign study product consume within 15 min standard breakfast meal ( = 0 h ) . Subjects remain clinic provided second serving assign study product consume within 15 min standard lunch meal t= 4 ± 0.5 h. Subjects provide third fourth serving assign study product instruct consume study product entirety within 15 min also provide afternoon snack , even dinner , respectively , allow least 3 h eating occasion . Compliance dispense product meal consumption confirm diet record . Subjects also instruct complete GI Tolerability Questionnaire next morning ( t=24h ) overnight fast ( 9-14h ) . A Bowel Habits Diary complete initial study product consumption ( t= 0 ) subsequent clinic visit ( t= 48 h ) . Subjects return clinic t= 48 h ( Visits 3 , 5 , 7 , 9 , 11 ) overnight fast ( 9-14 h ) complete test period , time 48 h GI Tolerability Questionnaire also complete . A washout period 7 occur test period ( e.g. , Visits 4 , 6 , 8 , 10 ) , subject return clinic cross next study product test sequence .</detailed_description>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Signs Symptoms , Digestive</mesh_term>
	<criteria>Subject male female , 1854 year age , inclusive . Subject body mass index ( BMI ) ≥18.50 ≤39.99 kg/m2 visit 1 ( day 7 ) weight stable ( ± 4.5 kg ) previous 3 month . Subject judge good health basis medical history . Subject willing maintain habitual diet physical activity pattern , include habitual use study approve medication and/or dietary supplement throughout study period . Subject willing avoid foods/beverages cause GIdistress , well highfiber food 24 h prior test visit . Subject understands study procedure sign form provide informed consent participate study authorization release relevant protect health information study Investigators . Subject report clinically important GI condition would potentially interfere evaluation study product ( e.g. , inflammatory bowel disease , irritable bowel syndrome , history surgery weight loss , gastroparesis , clinically important lactose intolerance ) . History presence clinically important endocrine ( include type 1 2 diabetes mellitus ) , cardiovascular , pulmonary , biliary , renal , hepatic , pancreatic , neurologic disorder , opinion Investigator , could interfere interpretation study result . Recent history ( within 6 week screen , visit 1 ) constipation ( define &lt; 3 bowel movement per week ) , and/or diarrhea ( define ≥3 loose liquid stools/d ) . Recent ( within 6 week screen , visit 1 ) episode acute GI illness nausea , vomit diarrhea . Daily use nonsteroidal antiinflammatory drug ( NSAIDS ) , Daily use antacid , proton pump inhibitor , and/or H2 blocker . Recent use antibiotic ( within 3 month visit 2 , day 0 ) . Use medication ( overthecounter prescription ) dietary supplement ( within 3 week visit 2 , day 0 ) know influence GI function constipation medication supplement ( include laxative , enema , fiber supplement and/or suppository ) ; antidiarrheal agent ; antispasmodic ; prebiotic probiotic supplement . Extreme dietary habit , include limited vegetarian diet intentional consumption high fiber diet . Known allergy sensitivity food ingredient : soy , dairy ( milk ) , wheat , egg , peanut , tree nut , fin fish crustacean . Uncontrolled hypertension ( systolic blood pressure ≥160 mm Hg diastolic blood pressure ≥100 mm Hg visit 1 , day 7 ) . History cancer prior two year , except nonmelanoma skin cancer . Any major trauma surgical event within 2 month visit 2 , day 0 . Females pregnant , plan pregnant study period , lactate , woman childbearing potential unwilling commit use medically approve form contraception throughout study period . Exposure nonregistered drug product within 30 day previous screen visit . Recent history ( within 12 month visit 1 ) strong potential alcohol substance abuse . Alcohol abuse define &gt; 14 drink per week ( 1 drink = 12 oz beer , 5 oz wine , 1½ oz distil spirit ) . Recent history ( within 2 month visit 1 ) use tobaccocontaining product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Gastrointestinal tolerability</keyword>
	<keyword>dietary fiber</keyword>
	<keyword>clinical trial</keyword>
	<keyword>healthy subject</keyword>
</DOC>